As suggested by recent studies, it is possible that new targets become available for PAX8 in ovarian cancer due to the reprogramming of PAX8 cistrome by epigenetic modifications that occur during tumorigenesis [19, 21, 22]. Here, PAX8 is linked to ovarian carcinoma.